ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 1.34 USD 5.51% Market Closed
Market Cap: 132.9m USD
Have any thoughts about
ADC Therapeutics SA?
Write Note
Section:
 

Relative Value

The Relative Value of one ADCT stock under the Base Case scenario is 4.96 USD. Compared to the current market price of 1.34 USD, ADC Therapeutics SA is Undervalued by 73%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ADCT Relative Value
Base Case
4.96 USD
Undervaluation 73%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
58
vs Industry
83
Median 3Y
2.3
Median 5Y
2.1
Industry
6.7
Forward
1.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1
Median 5Y
-2
Industry
21.9
Forward
-0.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.5
Industry
19.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-1.9
Industry
22.5
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
52
Median 3Y
-0.9
Median 5Y
3.9
Industry
2.4
More Details
4.5
EV/S
EV/S
Enterprise Value to Sales
4.5
vs History
40
vs Industry
63
Median 3Y
3.8
Median 5Y
3.6
Industry
7.1
Forward
4.2
More Details
4.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.9
vs History
33
vs Industry
66
Median 3Y
4
Median 5Y
3.7
Industry
9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.6
Industry
3.7
Forward
-1.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.5
Industry
3.4
Forward
-2.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-3.3
Industry
4.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-3.2
Industry
3.4
More Details
5.9
EV/IC
EV/IC
Enterprise Value to IC
5.9
vs History
62
vs Industry
29
Median 3Y
4.5
Median 5Y
7.2
Industry
4.5
More Details

Multiples Across Competitors

ADCT Competitors Multiples
ADC Therapeutics SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
ADC Therapeutics SA
NYSE:ADCT
132.5m USD 1.9 -0.8 -2.5 -2.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 726 371.3 -169 802.1 -206 193.9 -203 841
US
Abbvie Inc
NYSE:ABBV
333.8B USD 5.9 78.9 15.6 23.6
US
Amgen Inc
NASDAQ:AMGN
146.3B USD 4.3 24.7 13.5 22.2
US
Gilead Sciences Inc
NASDAQ:GILD
127.3B USD 4.4 21.4 9.4 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.1B USD 10.2 -114.3 24.3 25.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 971.9 -503.2 -547.9 -533.3
AU
CSL Ltd
ASX:CSL
116.6B AUD 4.9 27.1 16.7 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD 4.4 13.8 12.3 13.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.7B USD 14.8 -128.5 -571.8 -286.5
NL
argenx SE
XBRU:ARGX
29.8B EUR 15.1 39.7 -2 246.9 -1 506.4
P/S Multiple
Revenue Growth P/S to Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average P/S: 3 248 037.2
1.9
29%
0.1
FR
Pharnext SCA
OTC:PNEXF
35 726 371.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.4
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
1 971.9
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
5%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.8
30%
0.5
NL
argenx SE
XBRU:ARGX
15.1
39%
0.4
P/E Multiple
Earnings Growth PEG
CH
ADC Therapeutics SA
NYSE:ADCT
Average P/E: 34.3
Negative Multiple: -0.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -169 802.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.9
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.7
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21.4
187%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -503.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.1
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.8
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -128.5 N/A N/A
NL
argenx SE
XBRU:ARGX
39.7
28%
1.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average EV/EBITDA: 15.3
Negative Multiple: -2.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -206 193.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.6
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
7%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -547.9 N/A N/A
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
14%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -571.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 246.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average EV/EBIT: 19.8
Negative Multiple: -2.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -203 841 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.2
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.8
13%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -286.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 506.4 N/A N/A

See Also

Summary
ADCT intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADCT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADCT stock valuation using valuation multiples.
Wall Street Estimates
ADCT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADCT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.